EIP Pharma
Cambridge Massachusetts UNITED STATES
John Alam is an industry leader in translational medicine and has a track record of creating value to help build companies through clinical development success. Until May 2014, he was therapeutic area head for diseases of aging within Sanofi R&D. In that role he led all discovery and development activities at Sanofi directed at Alzheimer’s disease, as well as a number of other age-related diseases (Sarcopenia/Frailty, Osteoarthritis, Chronic Pain, others). Previously, from 1997 until 2008 he held positions of increasingly responsibility at Vertex Pharmaceuticals, Inc., including Chief Medical Officer and Executive Vice President Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. And, from 1991 to 1997, at Biogen, Inc, he led the clinical development of Avonex (interferon beta-1a) for multiple sclerosis. John currently is also a member of the board of directors of Alliance for Aging Research (AAR), a Washington DC based non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. Among other activities AAR convenes ACT-AD ("Accelerate Cures/Treatments for Alzheimers Disease"), a public-private partnership focused on accelerating the development of treatments that slow, halt or reverse the progression of Alzheimers disease. John received a S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Subsequently, he completed an internal medicine residency at Brigham and Women’s Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.
None yet.